{"id":"double-blind-adalimumab-placebo-mtx","safety":{"commonSideEffects":[{"rate":"12-15","effect":"Injection site reactions"},{"rate":"7-10","effect":"Upper respiratory tract infections"},{"rate":"5-8","effect":"Headache"},{"rate":"3-5","effect":"Nausea"},{"rate":"1-3","effect":"Serious infections (tuberculosis, opportunistic)"},{"rate":null,"effect":"Malignancy risk"}]},"_chembl":{"chemblId":"CHEMBL1201580","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Adalimumab is a fully human monoclonal antibody that binds to and neutralizes TNF-alpha, a key pro-inflammatory cytokine. When combined with methotrexate (MTX), a disease-modifying antirheumatic drug (DMARD), the dual mechanism provides synergistic suppression of inflammatory pathways in autoimmune conditions. This combination is standard-of-care for rheumatoid arthritis and other TNF-driven inflammatory diseases.","oneSentence":"Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling to reduce inflammation, combined with methotrexate for enhanced immunosuppressive effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:09:49.360Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis (in combination with methotrexate)"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Psoriasis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT02629159","phase":"PHASE3","title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2015-12-01","conditions":"Rheumatoid Arthritis","enrollment":1629},{"nctId":"NCT02889796","phase":"PHASE3","title":"Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-30","conditions":"Rheumatoid Arthritis","enrollment":1759},{"nctId":"NCT02833350","phase":"PHASE2","title":"Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-09-09","conditions":"Rheumatoid Arthritis","enrollment":578},{"nctId":"NCT04154852","phase":"PHASE2","title":"ADalimumab in Persistent Early Oligoarthrits Study (ADEOS)","status":"COMPLETED","sponsor":"University of Leeds","startDate":"2011-06","conditions":"Oligoarthritis","enrollment":22},{"nctId":"NCT01710358","phase":"PHASE3","title":"A Study in Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":1307},{"nctId":"NCT01251614","phase":"PHASE3","title":"A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2010-12","conditions":"Plaque Psoriasis","enrollment":114},{"nctId":"NCT02349451","phase":"PHASE2","title":"A Phase 2 Study to Investigate the Safety, Tolerability and Efficacy of ABT-122 in Subjects With Active Psoriatic Arthritis (PsA) Who Have an Inadequate Response to Methotrexate (MTX)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2015-04-28","conditions":"Psoriatic Arthritis","enrollment":240},{"nctId":"NCT00298272","phase":"PHASE2","title":"Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Biogen","startDate":"2006-05","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT01004432","phase":"PHASE3","title":"Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-12","conditions":"Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases","enrollment":433},{"nctId":"NCT00195663","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie (prior sponsor, Abbott)","startDate":"2000-12","conditions":"Early Rheumatoid Arthritis","enrollment":799},{"nctId":"NCT00420927","phase":"PHASE4","title":"Study of the Optimal Protocol for Methotrexate and Adalimumab Combination Therapy in Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Abbott","startDate":"2006-12","conditions":"Rheumatoid Arthritis","enrollment":1032},{"nctId":"NCT00195702","phase":"PHASE3","title":"Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.","status":"COMPLETED","sponsor":"Abbott","startDate":"2000-02","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT00048542","phase":"PHASE3","title":"Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","sponsor":"Abbott","startDate":"2002-09","conditions":"Arthritis, Juvenile Idiopathic","enrollment":171},{"nctId":"NCT00235820","phase":"PHASE3","title":"Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","status":"COMPLETED","sponsor":"Abbott","startDate":"2005-07","conditions":"Psoriasis","enrollment":271}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["ABT-D2E7","Humira"],"phase":"phase_3","status":"active","brandName":"Double-Blind Adalimumab/Placebo + MTX","genericName":"Double-Blind Adalimumab/Placebo + MTX","companyName":"Abbott","companyId":"abbott","modality":"Biologic","firstApprovalDate":"","aiSummary":"Adalimumab is a TNF-alpha inhibitor that blocks tumor necrosis factor-alpha signaling to reduce inflammation, combined with methotrexate for enhanced immunosuppressive effect. Used for Rheumatoid arthritis (in combination with methotrexate), Polyarticular juvenile idiopathic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}